Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
Farnesol: from perfume to Parkinson’s
A ground-breaking Cure Parkinson’s supported study that involved screening over 230,000 molecules has identified farnesol, a commonly found aromatic oil, as a new potential treatment of Parkinson’s.
Is Inhibikase ‘Abl’ to beat nilotinib in treating Parkinson’s?
Inhibikase Therapeutics has designed a novel drug that is similar to the drug nilotinib – previously tested in people with Parkinson’s – but is better at reaching its target in the brain.
Cure Parkinson’s launches legacy campaign
On 27 October, 50 long-time supporters of Cure Parkinson’s gathered at Micklefield Hall in Sarratt, Hertfordshire for the launch of our legacy campaign, Planting for a Cure.
Mo better for TEVA with Modag?
This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b. Anle138b is a small molecule inhibitor of the believed […]
Webinar: Deep Brain Stimulation (DBS)
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. In this webinar, Professor Patrik Brundin chairs a panel of experts featuring: Professor Helen Bronte-Stewart Stanford University, California; Professor Tom Foltynie, University College London and David Jones, a pharma entrepreneur who has…